Hover over image to zoom
BIO CLINIC DGL 400MG CHOCOLATE COCONUT DREAM 90 CHEWABLE TABS

BIO CLINIC DGL 400MG CHOCOLATE COCONUT DREAM 90 CHEWABLE TABS

By: BIO CLINIC

25340

CA$13.95
Out of Stock. This item ships in 1-2 weeks

Product Description

BENEFITS
DGL chewable tablets is the form associated with the greatest clinical efficacy, as it allows for licorice to be released in the stomach and dispersed/absorbed by the gastric mucosa
Provides 400 mg DGL per tablet, the clinically effective dosage
Deglycyrrhizination prevents adverse effects associated with licorice consumption
Delicious chewable tablets for better compliance
INGREDIENTS
Medicinal Ingredients

Serving Size: 1 Chewable Tablet
Servings per Container: 90
Each Tablet Contains:
Deglycyrrhizinated Licorice 10:1 Extract (Glycyrrhiza glabra) (root)................400 mg
Non-Medicinal Ingredients
Xylitol, microcrystalline cellulose, chocolate flavour, guar gum, cocoa powder, coconut flavour, purified water, stearic acid, vegetable grade magnesium stearate (lubricant), Stevia rebaudiana leaf.

Allergens:
Contains no artificial preservatives, colours or sweeteners and no dairy, soy, wheat, gluten or yeast. Sealed for your protection. Do not use if seal is broken. For freshness, store in a cool, dry place.
RECOMMENDED USE
Chew 1 tablet per day 20 minutes before each meal or as directed by a health care practitioner.
WARNINGS
Nearly all contraindications to DGL are due to pseudohyperaldosteronism or mineralocorticoid excess, effects which appear to be primarily due to glycyrrhizic acid. Although there are no apparent contraindications for DGL, patients with hypertension, congestive heart failure and hypokalemia should be monitored carefully. The safety of DGL in pregnancy and breastfeeding is unknown and should be used with caution. Consult a health care practitioner if symptoms persist or worsen. Keep out of reach of children.

Drug Interactions
No known drug interactions. Licorice influences the activity of several cytochrome enzymes, and reduces warfarin activity in animal models, likely due to glycyrrhizic acid activity. Thus DGL use should be carefully monitored in these patients.